

USC unveils new medical office building plans

With the number of private patients at USC steadily rising, USC and Tenet are moving ahead with plans to significantly expand patient care facilities on the Health Sciences Campus.

Later this year, USC and Tenet will break ground on two major building projects: the Healthcare Consultation Center II and a 10-story tower addition to USC University Hospital.

The \$49-million HCC II is a four-story medical office building that will be built on the corner of San Pablo and Alcazar streets, stretching to the entrance of the Eamer Medical Plaza. At 238,000 square feet, HCC II will be roughly twice the size of the current Healthcare Consultation Center. It will include two underground levels of parking as well as adjacent surface parking for patients.

USC Care Medical Group is leading the planning for HCC II, working closely with Bob Stephenson, USC's new associate senior vice president for capital construction development, who is overseeing the construction.

"HCC II is being designed for the most flexibility and highest level of customer service in our patient care delivery," said Jeffrey Huffman, president and CEO of USC Care Medical Group. "The design will allow medical practices to expand or contract over time based on patient volumes. Each floor will offer core services such as patient waiting and reception areas, exam rooms, consultation areas and conference rooms."

A courtyard area will span between HCC II and the HCC. The courtyard will include a walkway entrance from USC University Hospital and its parking structure.

The building design will feature several entrances to help alleviate traffic coming in and out of the Eamer Medical Plaza drive. A special drop-off area will be built off the lower Plaza entrance, or patients may enter off of Alcazar Street.

The first floor of the HCC II will be dedicated to a new USC University Hospital Outpatient Surgery Center and diagnostic imaging facilities, including MRI and CT scanning.

Other planned tenants for HCC II include orthopaedic surgery, psychiatry, anesthesia's pain management program, neurology, head and neck surgery, and gynecology. The build-



An architectural rendering shows the completed HCC II building as seen from the Eamer Plaza entrance on San Pablo Street. The \$49 million, four-story building is roughly double the size of the current Healthcare Consultation Center.

ing will also include a multi-disciplinary medical clinic for special programs and services.

According to Huffman, the planning team intends to make it a medical office building for the 21st century: All clinic spaces will be wired for digital charting and electronic record keeping.

"We are currently testing several

of these state-of-the-art systems in our newly opened USC Executive Health and Imaging Center in downtown Los Angeles," said Huffman. "The smaller scale of our Executive Health Center provides us with a perfect setting to test personal digital assistants or PDAs, wireless downloading of patient information and other advances that will soon become

standard to all medical settings."

The exterior of the building has been designed by RBB Architects to compliment the nearby existing facilities. The building will include precast concrete panels made from the same mix as the Neurogenetic Institute building now under construction, as well as matching glass.

See **HOSPITAL**, page 4

USC construction chief builds on experience

Bob Stephenson oversees new expansion

Bob Stephenson, who joined USC in September 2001 as associate senior vice president for capital construction development, has been around the building business his entire life. His family owned a mechanical contracting business in Florida, and he went on to establish his own career in construction management in Houston during its boom years. There he constructed post offices, schools and office buildings. He also served as an owner's representative for construction projects throughout the United States.

While acting as an owner's representative for a downtown Los Angeles project, he met a local developer and accepted a project management position with North Mulholland Properties Inc. In 1993, the owner of NMPI offered Stephenson a position

with MiniMed Inc.—a quickly growing, world class medical device manufacturing firm—which Stephenson accepted.

As senior director of plant management for MiniMed, Stephenson was responsible for all aspects of the company's physical plants including environmental compliance, safety, security and the planning and construction of new facilities. In 1999, he oversaw completion of a 19-acre, four-building, 500,000-square-foot world headquarters and manufacturing facility for MiniMed.

USC leaders learned of Stephenson through MiniMed founder and USC Trustee Alfred Mann. Stephenson had gained a great deal of relevant knowledge and experience through his eight years of working closely with scientific



Jon Nalick

Bob Stephenson

researchers in the medical and engineering fields at MiniMed. He and Mann had offered important counsel to the university relative to construction management techniques that had proved cost-effective on previous projects.

See **BUILD**, page 3

Pair of articles published USC researchers show both sides of NHEJ pathway

Pinpointing oxygen as the cause of routine chromosome damage and defining the role of a key protein in the repair of that damage are the subjects of two recently published papers from the laboratory of USC/Norris Comprehensive Cancer Center pathologist Michael Lieber.

The first paper was published in the March 5 issue of *Current Biology*; the other is slated for the March 22 issue of *Cell*, but was posted on the journal's Web site on March 1 as part of the journal's "immediate early publication process."

The *Cell* paper reveals that a protein previously linked to a devastating form of immunodeficiency plays a key role in repairing DNA. The repair system pathway is the same one used by the immune system to make antibodies.

Lieber is the Rita and Edward Polusky Chair in Basic Cancer Research at the Keck School of Medicine of USC.

About 15 percent of the cases of human severe combined immunodeficiency syndrome (SCID, known colloquially as "bubble boy" disease) are caused by the mutation of a specific gene and its protein product. In April of 2001, a team of French researchers tracked down that gene, and named it and its product Artemis (after the Greek goddess for the protection of children); they had no idea at all, however, what kind of protein it was, nor what its function might be.

Enter Lieber and graduate student Yunmei Ma. Lieber, Ma and their colleagues from the University of Ulm in Germany conclusively demonstrated that Artemis is a key protein in the repair of double-stranded DNA breaks, a process called NHEJ (non-homologous DNA end joining). In the NHEJ pathway, explained Lieber, the ends of the

See **LIEBER**, page 3

USC/Norris to begin clinical trial of vaccine for colon cancer

Oncologists at the USC/Norris Comprehensive Cancer Center will soon begin a clinical trial to evaluate a unique vaccine therapy in the treatment of metastatic colorectal cancer.

USC/Norris is one of several sites in the United States and Canada participating in the trial.

The multi-center trial will enroll up to 90 patients with previously untreated metastatic colorectal cancer, according to Heinz-Josef Lenz, associate professor of medicine and director of USC/Norris's gastrointestinal oncology program. Lenz hopes to recruit 10 to 20 patients.

"The goal of the study is to determine if the vaccine, called ALVAC-CEA/B7.1, can activate the body's own immune system to eliminate cancer cells that may not be eliminated with traditional treatment of metastatic colorectal cancer with the standard, first-line chemotherapy regimen," Lenz says. "We will be looking to see if the vaccine, combined with chemotherapy, allows a better outcome for patients than chemotherapy alone."

The Phase II trial will assess safety and immune activity.

Typically, vaccines such as those for chicken pox or measles are designed to prevent diseases by priming the immune system for a possible

attack. With therapeutic cancer vaccines, though, the goal is to "turn on" the immune system of people who already have the disease, to increase the power of current treatments such as chemotherapy.

While the immune system exists to respond to invaders, attack them and rid them from the body, it has a hard time recognizing cancer cells as targets because cancer cells arise from the body's own tissue.

The colon cancer vaccine under study consists of a form of live virus engineered to stoke the body's immune system in a specific way to battle cancer.

ALVAC is a variant of the canarypox virus; it produces a self-limiting infection that does not cause any harm or symptoms in humans.

This is how it works:

Most colorectal cancers over-express a protein called carcinoembryonic antigen, or CEA.

If the immune system could come to recognize CEA as a sign of something foreign or



Heinz-Josef Lenz

abnormal, it would then detect and attack cancer cells that have this CEA on their surface.

That is where the vaccine comes in. The virus variant in the vaccine is engineered to cause infected cells in the body to temporarily display CEA, which signals the immune system to attack tumor cells with CEA on their surface.

In the clinical trial, patients will be divided into three groups.

One group will be vaccinated before starting standard chemotherapy (and then receive a vaccine injection weekly during the chemotherapy regimen).

A second group will receive that same treatment as well as a tetanus shot, to see if that boosts immune response.

A third group will receive standard chemotherapy, and those who respond to the chemotherapy will have the option of receiving the vaccine at the end of the trial if they like.

Standard, first-line therapy for metastatic

colorectal cancer involves combination chemotherapy with three agents: Camptosar (irinotecan or CPT-11), 5-fluorouracil and leucovorin.

The investigational vaccine and other ALVAC-based formulations have shown promise in early clinical studies of the vaccine as a single agent.

The trials were conducted by the National Cancer Institute in collaboration with Therion Biologics of Cambridge, Mass. Treatments generally were well-tolerated, and side effects associated with the vaccine included mild, local reactions.

Lenz believes that in the future, such immunotherapies may be combined with genetically tailored chemotherapy regimens to create treatments that have the greatest chance of success for each individual patient.

Other clinical trial sites include centers in Washington D.C., Philadelphia, New York City, Birmingham, Ala., Chicago; Dunmore, Penn. and Ottawa, Canada. Aventis Pasteur Limited of Toronto, Canada is the study sponsor.

For information about Lenz's clinical trial, contact the USC/Norris Clinical Investigation Support Office at 865-0451.

—Alicia Di Rado

Janet Bickel, expert on women's leadership development, slated for April 4 lecture

The Health Sciences Women Faculty Association will host speaker Janet Bickel, a nationally known expert on women's professional development and leadership, on April 4.

Bickel, associate vice president and director for women's programs for the Association of American Medical Colleges, currently oversees an initiative to stimulate women's leadership development in academic medicine.

She has presented and consulted with many organizations and associations on professional and leadership development issues.

A member of the Presidential Commission on Women in Higher Education of the American Council on Education, she has also published extensively on medical education topics as primary author in the *The New England Journal of Medicine*, *Academic Medicine*, *the Journal of the American Medical*

Association and the *Journal of Medical Education*.

Her presentation, "Maximizing Your Professional Advancement: Options for Women," will focus on developmental issues that women in medicine and the health sciences face as they progress in their careers.

Bickel, a member of the Association of American Medical Colleges task force that recently completed a national study entitled

"Increasing Women's Leadership in Academic Medicine," will present some of the results of that study during her visit. Furthermore, she will offer suggestions for maintaining career advancement.

Her forum will run from 4:30 p.m. to 6 p.m. at the Edmondson Faculty Center. The event is free and open to the public. For more information, call Maria Ramirez in the Office for Women at 442-2554.

BUILD: Sense of accomplishment from making labs where scientists fight disease

Continued from Page 1

In September 2001—the same time that MiniMed was acquired by Medtronic Corporation—USC asked Stephenson to join its building program on both University Park and Health Sciences campuses.

"I thought it to be a great fit, and I quickly accepted," said Stephenson.

With Stephenson's arrival, the university created the USC Department of Capital Construction Development. In addition to

Stephenson, the department includes: Project Managers Stan Westfall, Maria Morgan and William Marsh; Senior Business Officer Denise Freeman; and Administrative Assistant Cynthia Wright.

Since its first two major projects—the Healthcare Consultation Center II and the Harlyne J. Norris Cancer Research Tower—are on the Health Sciences Campus, USC's capital construction department set up operations in a mobile office on the corner of Alcazar and San

Pablo streets.

"The members of the capital construction development team are focused, committed and motivated to accomplish the university's aggressive growth goals," said Stephenson.

"I've always felt a sense of accomplishment when completing a new building," he added, "but I'm sure that feeling will deepen as I reflect on the future scientific discoveries and the development of promising scholars that will take shape in these new buildings."

HSC Newsmakers

On March 10, oncologist **Heinz-Josef Lenz** appeared live on the syndicated national radio show, "The Group Room," which focused on colorectal cancer.

The March 11 *Los Angeles Downtown News* ran a story on fertility expert **Richard Paulson** and the 15th anniversary of the USC Reproductive Endocrinology and Infertility Clinic.

Also in the March 11 *Los Angeles Downtown News* was a story on Stevia, a natural flavor alternative to sugar. The story referenced work done by cardiovascular researcher Howard Hodis.

On March 11, Gov. Gray Davis announced that \$200,000 was being devoted to study the efficacy of a biomedical research park at the

Health Sciences Campus. The story appeared on the City News Service and in the *Silicon Valley/San Jose Business Journal*.

On March 12, KPCC-FM's "Talk of the City" focused on anxiety and depression six months after the Sept. 11 attacks. Psychiatrist **Bruce Spring** was a featured guest on the show.

HSC Weekly

HSC Weekly is published on Fridays, except for academic holiday periods. Copies are distributed throughout the Health Sciences Campus, University of Southern California. It is written and produced by the staff of Health Sciences Public Relations. Permission to reprint articles with attribution is freely given.

Editor: Jon Nalick
Associate Vice President, Health Sciences Public Relations: Brenda Maceo
Senior Vice President, University Relations: Martha Harris

Contributors: Alexis Bergen, Matt Blakeslee, Alicia Di Rado, Greg Kerr, Alfred Kildow, Brenda Maceo, Jon Nalick, Lori Oliwenstein, LaCarol Pratt, Richard Stone, Mary Ellen Stumpfl, Carol Varma and Jon Weiner

323/442-2830
FAX: 323/442-2832
hscwkly@hsc.usc.edu
www.usc.edu/hsc/info/pr/

USC neurosurgeon tapped for Nobel forum on consciousness

Michael L.J. Apuzzo, professor of neurological surgery and holder of the Edwin M. Todd-Trent H. Wells, Jr., Professorship in Neurological Surgery, will deliver a Nobel Forum lecture at Sweden's Karolinska Institute on March 20.

Sponsored by the Institute's Cultural Council, the presentation is part of a panel of lectures dealing

with the topic of consciousness as a subjective experience.

Apuzzo was selected to represent the field of neurosurgery in an international panel of scholars, which includes Nobel laureates representing the fields of molecular biology, philosophy, and the cognitive and basic neurosciences.

Other notable participants in the

lecture forum include: Columbia University's neuroscientist Eric Kandel; UC Berkeley philosopher John Searle; Pasteur Institute molecular biologist Jean-Pierre Changeux; University of Basel molecular biologist



Michael L.J. Apuzzo

Andreas Engel; and University of Oregon cognitive psychologist Michael Posner.

Apuzzo is known for his contributions to the field of cerebral surgery and has previously been honored by the institute with its Herbert

Olivecrona Medal.

His presentation on "The Realm of Consciousness: Fabrication of the Human Mind" will discuss a neurosurgical perspective on issues of memory and consciousness and explore philosophical perspectives, anatomy, physiology, molecular biology and contemporary surgical experiences.

LIEBER: Oxygen in the air we breathe may sow seeds of our own destruction

Continued from Page 1

broken DNA strands are trimmed and rejoined to one another. "What Artemis does is trim away the damaged parts of the DNA so that the strands can be joined," said Lieber.

Artemis and the NHEJ pathway are so essential, Lieber continued, that mice lacking NHEJ usually die at birth; those that don't die generally lack an immune system and experience accelerated aging.

As previous studies have shown, humans with a defective Artemis protein also wind up without any immune defense to speak of.

That, said Lieber, is because the immune system creates its defenses by cutting and then rejoining bits of nuclear DNA (the rejoining relies on NHEJ).

Without Artemis, the cells can't create the antibodies necessary to go after the myriad pathogenic invaders that are regularly encountered.

Being unable to cut and splice DNA can sometimes be of benefit. "What we're going to do next, is try to screen for drugs that inhibit Artemis, because this might be useful from a cancer therapy standpoint," said Ma, the paper's first author. If we could just give a pulse of drug inhibitor for a while, we might be able to focus the effects of radiation therapy, for instance, by

not allowing the cancer cells to repair themselves after being hit with the radiation."

Still, noted Lieber, for normal cells, Artemis and the NHEJ pathway are critical for survival because DNA is vulnerable to damage. A sample of cells viewed under a microscope will reveal that 5 to 10 percent of them have at least one broken chromosome.

Normally the NHEJ pathway works to fix those breaks.

But the NHEJ pathway doesn't always function at full capacity. A paper published by Lieber, M.D./Ph.D. student Zarir E. Karanjawala and Norris Cancer Center researcher Chih-Lin Hsieh in 1999 found that when the NHEJ pathway is disabled or missing, the number of cells with at least one chromosome break in a sample climbs to 60 percent.

In the March 5 issue of *Current Biology*, Karanjawala, Lieber, and colleagues demonstrate that the breakage comes from a most ubiquitous source: oxygen.

Originally, said Karanjawala, the authors had wondered if the damage might be coming from some environmental source, perhaps from background radiation.

But when they looked more closely, said Karanjawala, they found it was in the air people breathe. "It's coming from the oxygen,"

Karanjawala explained. "We found that if you vary the oxygen levels in which cells are grown, the breakage levels of the chromosomes vary as well—the higher the oxygen level, the more breakage you'll see."

The oxygen causes its damage, Lieber said, through oxidative free radicals—highly reactive atoms with an unpaired electron that rips through cells "like a bullet."

"Our bodies are being riddled with these bullets every day, whether we like it or not," explained Lieber.

"And the sorts of double-strand DNA breaks we were looking at are hard to repair. Even if you put the two ends together as best you can, you usually lose a couple of nucleotides along the way. And so every time we get an oxidative free radical hit, which happens several times per day per cell, we lose a little info. Every time it hits your DNA, you wind up with a little less genetic information than you had when you started the day," he said.

The solution? Frankly, said Lieber, there may be none. "Oxygen—can't live with it, can't live without it," he said. "We need it to survive, but ultimately, it's also probably what kills us."

Yunmei Ma, Ulrich Pannicke, Klaus Schwarz and Michael R. Lieber, "Hairpin Opening and Overhand Processing by an Artemis/DNA-Dependent Protein Kinase Complex in Nonhomologous End Joining and V(D)J Recombination." Cell Immediate Early Publication, March 1, 2002, <http://www.cell.com>

Zarir E. Karanjawala, Niamb Murphy, David R. Hinton, Chih-Lin Hsieh and Michael R. Lieber, "Oxygen Metabolism Causes Chromosome Breaks and Is Associated with the Neuronal Apoptosis Observed in DNA Double-Strand Break Repair Mutants." Current Biology, Vol. 12, pp. 397-402, March 5, 2002.

—Lori Oliwenstein

The Ninth Annual Joseph P. Van Der Meulen Symposium in Clinical Neuroscience

Advances in the Treatment of Neurologic Disorders

March 22, 2002

Louis B. Mayer Auditorium

Sessions include:

8:15 a.m. Alzheimer's Disease Treatment—Helena Chui

8:45 a.m. Parkinson's Disease Treatment—Mark F. Lew

9:15 a.m. Multiple Sclerosis Treatment—Leslie P. Weiner

9:45 a.m. Nerve Blocks for Pain—Steven H. Richeimer

10:30 a.m. Reflex Sympathetic Dystrophy/Complex Regional Pain Syndrome—

Robert J. Schwartzman

11:15 a.m. Neuropathic Pain Treatment—Ahmad Beydoun

1 p.m. Migraine Headache Treatment—Neil Raskin

1:45 p.m. Medical Treatment of Brain Tumors—Marc C. Chamberlain

2:15 p.m. Surgical Treatment of Brain Tumors—Thomas C. Chen

3 p.m. Medical Stroke Treatment and Prevention—Gene Sung

3:30 p.m. Surgical Stroke Treatment and Prevention—George P. Teitelbaum

4 p.m. Antiepileptic Drugs: Uses Outside Epilepsy—David Y. Ko

6:30 p.m. Reception and Dinner at the Ritz-Carlton Huntington Hotel followed by the Van Der Meulen Lecture: The Neurology in Shakespeare—Lance Fogan

Symposium fee is \$50; the reception is \$75 per person. Pre-registration and prepayment is required. For more information and to register, call 442-2555 or 1-800-USC-1119.

Is it a compliance violation?

You make the call

When you call our Help Hotline you get the information you need to understand compliance issues. Like what laws, regulations and university policies really mean. And which ones apply to you.

If you have questions—or want to report a suspected violation—phone the Office of Compliance Help & Hotline at (213) 740-2500.

Because when it comes to compliance relying on our expertise is a very good call.



Office of Compliance

Help & Hotline: (213) 740-2500

HOSPITAL: New tower will add patient beds and operating rooms

Continued from Page 1

Punched windows will give it a look similar to the current HCC. An off-white exterior color will compliment USC University Hospital and Doheny Eye Institute colors.

Landscaped perimeters of the building along San Pablo and Alcazar will begin to define the northern edge of the Health Sciences Campus as proposed in the campus master plan.

"We are fortunate to have Bob Stephenson, Project Manager Stan Westfall and the team at RBB Architecture on our team," said Huffman. "This is an outstanding and experienced group, and I am confident that we will end up with the very highest quality of facility."

The HCC II complex is being built in concert with the planned expansion of USC University Hospital. The hospital's new 10-story tower will add 14 operating rooms, 48 inpatient beds, and four floors of unfinished shell space for future development. The tower, with an entrance off Norfolk Avenue, will expand surgical support and sterile areas, as well as pre- and post-operative areas. It is scheduled to open in December 2004. HCC II is scheduled for completion in December 2003.

—Brenda Maceo



From left, Brian Henderson, Richard Volk, Marjorie Lord Volk and Stephen J. Ryan flank a photo of the new Neurogenetic Institute during a Feb. 20 ceremony. The ceremony was held in recognition of a \$3 million gift from the Weingart Foundation, made in honor of Harry J. Volk.

Calendar

Tuesday, March 19

8 a.m. Neurology Grand Rounds "Pregnancy and MS: Current Perspectives," Wendy Gilmore, USC. Univ. Hospital, Troy Room. Info: 226-2639

9:30 a.m. Neurology Post Grand Rounds. "Journal Club," David Hoenig and Gene Sung, USC. Univ. Hospital, Troy Room. Info: 226-2639

11 a.m. Endocrinology and Diabetes Grand Rounds. "The Beta Cell and the Fat Cell in Type 2 Diabetes," Barbara Corkey, Boston Medical Ctr. AHC Aud., Room 102. Info: 442-2809

Noon. "How Proteins Mediate Ca²⁺ Dependent Membrane Fusion and Neurotransmitter Secretion," Thomas Martin, Univ. of Wisconsin. McKibben Hall, Room 256. Info: 442-2901

Noon. "Oral Health and Diseases in India," Naseem Shah, New Dehli. Guggenheim Hall, School of Dentistry, UPC. Info: (213) 740-2305

12:15 p.m. "The Impact of the Holocaust in Survivor Families: Treatment Focus," Robert Krell, Univ. of British Columbia. Hastings Aud., HMR. Info: 226-5572

5 p.m. "From TMD Symptoms to the Cause of Pain," Christian Stohler, Univ. of Michigan. Blair Room 160, School of Dentistry, UPC. Info: (213) 740-8095

6:30 – 10 p.m. Common Problems in Primary Care 2002. "Female Incontinence," David Ginsberg, USC; "Menopause and Hormone Replacement Therapy," Raquel Arias, USC; and "Breast Disease," Susana Gonzalez, USC. DEI, 3rd Floor Conf. Ctr. Info: 442-1313

Wednesday, March 20

7 a.m. Medicine Grand Rounds. "PML," John Leedom, USC. GNH, Room 1645. Info: 226-7591

Noon. "Insights Into the Neuropathy of Schizophrenia," Ted Jones, UC Davis. Hedco Aud., UPC. Info: (213) 740-9176

Thursday, March 21

Noon. Cellular Homeostasis Lecture Series. "Matricellular Proteins Regulate Cell-Matrix Interactions: Is There Life Without SPARC?" E. Helen Sage, Hope Heart Inst. AHC Aud., Room 102. Info: 442-3121

5:30 p.m. 7th Annual Joseph Boyes Memorial Lecture. "Contributions to Hand Function," Ronald Linscheid, Mayo Medical School. AHC Aud., Room 102. Info: 226-7204

Friday, March 22

Deadline: Scholarship applications for graduate and undergraduate students attending USC for the 2002-03 year. Info: (213) 740-4999

7 a.m. 9th Annual Joseph Van Der Meulen Symposium in Clinical Neuroscience. "Advances in the Treatment of Neurologic Disorders," various speakers. Mayer Aud. Info: 442-2555

7:15 a.m. 7th Annual Joseph Boyes Memorial Lecture. "Dynamic Factors in Carpal Stability," Ronald Linscheid, Mayo Medical School. McKibben Hall, Room 156. Info: 226-7204

Saturday, March 23

8 a.m. - 12:30 p.m. "5th Annual Program for People with Diabetes and Their Families: Healthy Living with

Diabetes" various speakers. Mayer Aud. Info: 442-2533

Monday, March 25

Noon. "Protein Crystallography: New Mechanisms and Amber-encoded Amino Acids," Michael Chan, Ohio State Univ. Norris Tower, 7th Floor Conf. Ctr. Info: 442-1244

Tuesday, March 26

8 a.m. Neurology Grand Rounds. "Case Presentation," Yafa Minazad, USC. Univ. Hospital, Troy Room. Info: 226-2639

9:30 a.m. Neurology Post Grand Rounds "Ataxias," Allan Wu, USC. Univ. Hospital, Troy Room. Info: 226-2639

6:30 p.m. – 10 p.m. Common Problems in Primary Care 2002. "New Trends in Diagnosis and Management of Prostate Cancer," Eila Skinner, USC; "New Trends in Multiple Sclerosis Research and Treatment," Norman Kachuck, USC; "HIV News for the Primary Care Physician," Peter Katsufakis, USC. DEI 3rd Floor Conf. Ctr. Info: 442-1313

Wednesday, March 27

7 a.m. Medicine Grand Rounds. "Hyperprolactinemia in Hodgkins," Peter Singer, USC. GNH Room 1645. Info: 226-7591

Thursday, March 28

Noon. Cellular Homeostasis Lecture Series. "Nuclear Receptors in Macrophage Lipid Metabolism and Atherosclerosis," Peter Tontonoz, UCLA. AHC Aud., Room 102. Info: 442-3121

5 p.m. "Dentin Demineralization, Hydration, and Ancient Wonder," Grayson Marshall, UCSF. UPC, Lecture

Room C, School of Dentistry, UPC. Info: (213) 740-8095

5:30 p.m. "Dentin Bonding and Flaws," Sally Marshall, UCSF. Lecture Room C, School of Dentistry, UPC. Info: (213) 740-8095

Tuesday, April 2

6:30 p.m. – 10 p.m. Common Problems in Primary Care 2002. "Diabetes Update," Peter Butler, USC; "Work-Up of the Thyroid Nodule" and "Otitis Media," Dennis Maceri, USC. DEI 3rd Floor Conf. Ctr. Info: 442-1313

Notice: Deadline for calendar submission is 4 p.m. Tuesday to be considered for that week's issue. Please note that timely submission does not guarantee an item will be printed. Send calendar items to HSC Weekly, DEI 2510 or fax to 442-2832, or e-mail to lpatt@hsc.usc.edu. Entries must include day, date, time, title of talk, first and last name of speaker, affiliation of speaker, location, and a phone number for information.

The HSC Calendar is online at <http://www.usc.edu/hsc/calendar.html>

**USC Health Sciences
Public Relations
1450 San Pablo Street
DEI 2510
Los Angeles, CA 90033**

**Non-Profit Organization
U.S. POSTAGE PAID
University of Southern
California**